4.19

0.48% 0.02

After Hours: 4.23 0.04 +0.95%

Neuphoria Therapeutics Inc (NEUP)

Overview News Price History Discussions Forecast

Neuphoria Therapeutics Inc stock is traded at $4.19, with a volume of 37,158. It is up +0.48% in the last 24 hours and up +11.14% over the past month. Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Previous Close:

$4.17

Open:

$4.17

24h Volume:

37,158

Relative Volume:

0.02

Market Cap:

$22.53M

Revenue:

$15.66M

Net Income/Loss:

$5.83M

P/E Ratio:

-0.1754

EPS:

-23.8939

Net Cash Flow:

$466.20K

1W Performance:

+1.95%

1M Performance:

+11.14%

6M Performance:

-48.90%

1Y Performance:

+20.06%

1-Day Range:

$4.124

$4.25

1-Week Range:

$3.98

$4.25

52-Week Range:

$3.4178

$21.40

Neuphoria Therapeutics Inc Stock (NEUP) Company Profile

Name

Neuphoria Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

781-439-5551

Address

100 SUMMIT DR, BURLINGTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NEUP's Discussions on Twitter

Compare NEUP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEUP Neuphoria Therapeutics Inc	4.19	22.42M	15.66M	5.83M	466.20K	-23.89
VRTX Vertex Pharmaceuticals Inc	468.41	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	753.55	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	814.74	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	357.98	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	339.32	37.49B	4.98B	69.59M	525.67M	0.5197

Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-28-23	Reiterated	Maxim Group	Buy
Jan-10-22	Initiated	Berenberg	Buy
Jan-10-22	Initiated	Cantor Fitzgerald	Overweight
Jan-10-22	Initiated	Evercore ISI	Outperform
Jan-10-22	Initiated	H.C. Wainwright	Buy

View All

Neuphoria Therapeutics Inc Stock (NEUP) Latest News

Jan 22, 2026

Can Neuphoria Therapeutics Inc. outperform in the next rallyMarket Sentiment Summary & Entry Point Confirmation Alerts - mfd.ru

Jan 22, 2026

Wall Street Recap: Whats the outlook for Neuphoria Therapeutics Incs sectorPortfolio Gains Report & Weekly Hot Stock Watchlists - baoquankhu1.vn

Jan 22, 2026

Jan 21, 2026

Exit Recap: What is the implied volatility of Lakeland Financial CorporationMarket Trend Report & Weekly Chart Analysis and Guides - baoquankhu1.vn

Jan 21, 2026

Neuphoria receives $15M milestone payment from Merck - MSN

Jan 21, 2026

Jan 14, 2026

Market Wrap: Will Neuphoria Therapeutics Inc outperform during market ralliesEarnings Risk Summary & Comprehensive Market Scan Insights - baoquankhu1.vn

Jan 14, 2026

Jan 13, 2026

Will Neuphoria Therapeutics Inc stock outperform value stocksStock Surge & Stepwise Entry/Exit Trade Alerts - Bộ Nội Vụ

Jan 13, 2026

Jan 11, 2026